Karishma Khullar1, Jesse J Plascak2, Richard Drachtman3, Peter D Cole3, Rahul R Parikh1. 1. Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. 2. Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ, USA. 3. Section of Pediatric Hematology and Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Abstract
BACKGROUND: The purpose of this study was to examine the factors associated with disparities in overall survival (OS) by race in pediatric diffuse large B-cell lymphoma (DLBCL) patients. METHODS: We evaluated clinical features and survival among patients ≤21 years of age diagnosed with stage I-IV DLBCL from 2004 to 2014 from the National Cancer Database (NCDB) using a multivariable Cox proportional hazards model. RESULTS: Among 1386 pediatric patients with DLBCL, 1023 patients met eligibility criteria. In unadjusted analysis, Black patients had a significantly higher overall death rate than White patients (HRBlack vs. White 1.51; 95% CI: 1.02-2.23, p = 0.041). The survival disparity did not remain significant in adjusted analysis, though controlling for covariates had little effect on the magnitude of the disparity (HR 1.46; 95% CI 0.93-2.31, p = 0.103). In adjusted models, presence of B symptoms, receipt of chemotherapy, stage of disease, and Other insurance were significantly associated with OS. Specifically, patients with B symptoms and those with Other insurance were more likely to die than those without B symptoms or private insurance, respectively (HR 1.75; 95% CI 1.22-2.50, p = 0.002) and (HR 2.56; 95% CI, 1.39-4.73, p = 0.0027), patients who did not receive chemotherapy were three times more likely to die than those who received chemotherapy (HR 3.10; CI 1.80-5.35, p < 0.001), and patients who presented with earlier stage disease were less likely to die from their disease than those with stage IV disease (stages I-III HR 0.34, CI 0.18-0.64, p < 0.001; HR 0.50, CI 0.30-0.82, p = 0.006, HR 0.72, CI 0.43-1.13, p = 0.152, respectively). CONCLUSIONS: Our results suggest that racial disparities in survival may be mediated by clinical and treatment parameters.
BACKGROUND: The purpose of this study was to examine the factors associated with disparities in overall survival (OS) by race in pediatric diffuse large B-cell lymphoma (DLBCL) patients. METHODS: We evaluated clinical features and survival among patients ≤21 years of age diagnosed with stage I-IV DLBCL from 2004 to 2014 from the National Cancer Database (NCDB) using a multivariable Cox proportional hazards model. RESULTS: Among 1386 pediatric patients with DLBCL, 1023 patients met eligibility criteria. In unadjusted analysis, Black patients had a significantly higher overall death rate than White patients (HRBlack vs. White 1.51; 95% CI: 1.02-2.23, p = 0.041). The survival disparity did not remain significant in adjusted analysis, though controlling for covariates had little effect on the magnitude of the disparity (HR 1.46; 95% CI 0.93-2.31, p = 0.103). In adjusted models, presence of B symptoms, receipt of chemotherapy, stage of disease, and Other insurance were significantly associated with OS. Specifically, patients with B symptoms and those with Other insurance were more likely to die than those without B symptoms or private insurance, respectively (HR 1.75; 95% CI 1.22-2.50, p = 0.002) and (HR 2.56; 95% CI, 1.39-4.73, p = 0.0027), patients who did not receive chemotherapy were three times more likely to die than those who received chemotherapy (HR 3.10; CI 1.80-5.35, p < 0.001), and patients who presented with earlier stage disease were less likely to die from their disease than those with stage IV disease (stages I-III HR 0.34, CI 0.18-0.64, p < 0.001; HR 0.50, CI 0.30-0.82, p = 0.006, HR 0.72, CI 0.43-1.13, p = 0.152, respectively). CONCLUSIONS: Our results suggest that racial disparities in survival may be mediated by clinical and treatment parameters.
Authors: Karishma Khullar; Zorimar Rivera-Núñez; Sachin R Jhawar; Richard Drachtman; Peter D Cole; Bradford S Hoppe; Rahul R Parikh Journal: Leuk Lymphoma Date: 2019-10-23
Authors: Richard Aplenc; Todd A Alonzo; Robert B Gerbing; Franklin O Smith; Soheil Meshinchi; Julie A Ross; John Perentesis; William G Woods; Beverly J Lange; Stella M Davies Journal: Blood Date: 2006-03-14 Impact factor: 22.113
Authors: Rodney R Miles; Martine Raphael; Keith McCarthy; Andrew Wotherspoon; Mark A Lones; Marie J Terrier-Lacombe; Catherine Patte; Mary Gerrard; Anne Auperin; Richard Sposto; Virginia Davenport; Mitchell S Cairo; Sherrie L Perkins Journal: Pediatr Blood Cancer Date: 2008-09 Impact factor: 3.167
Authors: Mary Gerrard; Mitchell S Cairo; Claire Weston; Anne Auperin; Ross Pinkerton; Anne Lambilliote; Richard Sposto; Keith McCarthy; Marie-José T Lacombe; Sherrie L Perkins; Catherine Patte Journal: Br J Haematol Date: 2008-03-26 Impact factor: 6.998
Authors: S Goldman; L Smith; J R Anderson; S Perkins; L Harrison; M B Geyer; T G Gross; H Weinstein; S Bergeron; B Shiramizu; W Sanger; M Barth; J Zhi; M S Cairo Journal: Leukemia Date: 2012-09-03 Impact factor: 11.528
Authors: Theresa H M Keegan; Christina A Clarke; Ellen T Chang; Sarah J Shema; Sally L Glaser Journal: Cancer Causes Control Date: 2009-12 Impact factor: 2.506